The talk of the town at this year’s American Society of Addiction Medicine annual conference was GLP-1 receptor agonists, generally known as medications to treat obesity. Mainstream media appears to mirror this trend as nearly every other radio and television ad seemingly involves a weight loss medication. In addition to treating obesity and Type 2 diabetes, GLP-1s have also shown promise with substance use disorders (SUD). Because so many questions exist about safety, efficacy, long-term effects and more, ASAM appropriately invited several scientists and clinicians to present the latest data on the role of GLP-1 RAs in addiction.
Mental Health and Substance Use Treatment Cost $139.6 Billion in 2021
U.S. spending on mental health and substance use treatment increased from $40.9 billion in 2000 to $139.6 billion in...
0 Comments